Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
- 1 January 2021
- journal article
- letter
- Published by Edra SpA in European Annals of Allergy and Clinical Immunology
- Vol. 53 (1), 47-48
- https://doi.org/10.23822/EurAnnACI.1764-1489.147
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticariaClinical and Experimental Immunology, 2020
- Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumabAllergy, 2018
- Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRIEuropean Journal of Immunology, 2018
- IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticariaJournal of Allergy and Clinical Immunology, 2018
- Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticariaAllergy, 2018
- The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaAllergy, 2018
- The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their changeAllergy, 2017
- Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticariaThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticariaAllergy, 2017
- Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trialsJournal of Allergy and Clinical Immunology, 2016